Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy

Worldwide, the most common cause of chronic kidney disease (CKD) and end stage renal disease (ESRD) is diabetes. Unlike the past, in south korea, diabetes account for more than 40% of ESRD. According to WHO reports in 1998, 100 million people had type 2 diabetes in 1997, and there is expected to increase by 300 million people in 2025. In addition, the expected survival time of patients with diabetes increase compared to previous. In the future, ESRD due to type 2 diabetes is expected to have a significant impact on the health industry. Therefore, prevention of progression to CKD and ESRD in diabetic patients is important to aspect of national health and economic problems. How to stop the progression of diabetic nephropathy is part of modern medicine to be solved.

Strict glycemic control, blood pressure regulation, and use of renin-angiotensin system (RAS) blockers inhibit the development and progression of diabetic nephropathy. Microalbuminuria in diabetic patients has been recognized as a predictor of progression of diabetic nephropathy. Thus, the prevention of elevated urinary albumin excretion is an important therapeutic target for the prevention of renal and cardiovascular events.

In patients with diabetes and hypertension, the drugs that block the RAS are used to treat proteinuria, but still a large number of patients with proteinuria are uncontrolled. In addition, ACE inhibitors or ARB agents actually have a limited effect on reducing the risk of cardiovascular or renal outcome. Also, sulodexide or pentoxyphylline which is reducing proteinuria have some weak evidence in terms of efficacy and safety. Therefore, the introduction of new alternative drugs are required.

Already several study reported that calcitriol or paricalcitol in the renal injury model have renopreventive effect. In addition, in diabetic renal injury mice model reported that vitamin D receptor deficiency leads to glomerulosclerosis. Inhibition of the RAS with combination of paricalcitol and RAS inhibitors effectively prevent renal injury in diabetic nephropathy. Recently, Dick de Zeeuw et al reported that addition of paricalcitol to RAS inhibition safely lower residual albuminuria in patients with diabetic nephropathy. Recent studies reported that elevated concentrations of serum markers of the TNFα and Fas-pathways are strongly associated with decreased renal function in diabetic patients. However, the role of these markers in early progressive renal function decline are not clear. Therefore, the objective of this study is to identify the renoprotective effect as an new treatment of activated vitamin D (Calcitriol) indicating the TNF-α-related anti-inflammatory action and to seek the role as an important biomarker that the changes of TNFR in diabetic nephropathy can predict response to treatment.

Study Overview

• Status: Unknown
• Conditions: Diabetic Nephropathy
• Intervention / Treatment: Drug: Placebo; Drug: Calcitriol

• Study Type: Interventional
• Enrollment (Anticipated): 276
• Phase: Phase 4

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of, 110-744
    • Recruiting
    • Seoul National University Hospital
    • Contact: Yonsu Kim, M.D., Ph.D; Phone Number: 82-2-2072-2264; Email: yonsukim@snu.ac.kr
    • Contact: Dongki Kim, M.D., Ph.D; Phone Number: 82-2-2072-2303; Email: dkkim73@gmail.com
    • Principal Investigator: Yonsu Kim, Ph.D.
    • Sub-Investigator: Dongki Kim, M.D., Ph.D
    • Sub-Investigator: Sumi Lee, M.D.
  • Seoul, Korea, Republic of
    • Not yet recruiting
    • Seoul National University Boramae Medical Center
    • Contact: Jungpyo Lee, M.D., Ph.D; Phone Number: 82-2-870-2261; Email: kjwa1@medimail.co.kr
    • Sub-Investigator: Jungpyo Lee, M.D., Ph.D

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• patients age 19-80 years
• Clinically proven diabetic nephropathy
• MDRD eGFR >= 30mL/min/1.73m2
• Patients with residual urine protein/creatinine ratio >= 200mg/g
• Adequate blood pressure control as treated systolic blood pressure <=140 or diastolic <=90 mmHg with RAS inhibitor for more than 3months
• Serum intact PTH <500 mg/dL
• Serum calcium <10.2 mg/dL
• Patients who have not been treated vitamin D within the 3months prior to signing the informed consent form

Exclusion Criteria:

• Patients age <19 years or > 80years
• Patients with rapidly progressive glomerulonephritis
• Patients requiring renal replacement therapy immediately
• Hypercalcemia(Uncorrected serum calcium level >10.2 mg/dL) within recent 3month
• Malignant hypertension
• Heart failure (New York Heart Association functional class II to IV or LVEF <40%)
• Severe chronic obstructive lung disease
• Decompensated liver disease (ALT >3X upper normal limit)
• Known allergy or hypersensitivity to vitamin D
• Current treatment with steroids and/or immunosuppressive agents
• Active primary malignancy requiring treatment or survival limits less than 2years
• History of noncompliance to medical regimen
• Inability to give an informed consent or to cooperate with researchers

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo
Experimental: Calcitriol	Drug: Calcitriol; dosage of 0.5mcg administered orally once daily for 12 month

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in renal function with proteinuria	Comparison of in GFR level from baseline Comparison of proteinuria amount checked by random urine protein/creatinine ratio	12 month after administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
changes in sTNFR and TNF-related proteins	Comparison of serum TNFR1, TNFR2 levels from baseline	12 months after administration

Collaborators and Investigators

• Sponsor: Seoul National University Hospital
• Investigators: Study Chair: Yonsu Kim, M.D., Ph.D, Seoul National University Hospital

Study record dates

Study Major Dates

• Study Start: October 1, 2012
• Primary Completion (Anticipated): April 1, 2014

Study Registration Dates

• First Submitted: August 21, 2012
• First Submitted That Met QC Criteria: August 24, 2012
• First Posted (Estimate): August 27, 2012

Study Record Updates

• Last Update Posted (Estimate): February 13, 2014
• Last Update Submitted That Met QC Criteria: February 12, 2014
• Last Verified: February 1, 2014

More Information

Terms related to this study

• Keywords: diabetic nephropathy; surrogate marker,; circulating soluble TNF receptor,
• Additional Relevant MeSH Terms: Urologic Diseases; Endocrine System Diseases; Diabetes Complications; Diabetes Mellitus; Kidney Diseases; Diabetic Nephropathies; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Micronutrients; Membrane Transport Modulators; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Vasoconstrictor Agents; Calcium Channel Agonists; Calcitriol
• Other Study ID Numbers: SNUH-TNFR